Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Cortes J, Faderl S, Estey E, Kurzrock R, Thomas D, Beran M, Garcia-Manero G, Ferrajoli A, Giles F, Koller C, O'Brien S, Wright J, Bai SA, Kantarjian H.
Cortes J, et al. Among authors: kurzrock r.
J Clin Oncol. 2005 Apr 20;23(12):2805-12. doi: 10.1200/JCO.2005.09.005. Epub 2005 Feb 22.
J Clin Oncol. 2005.
PMID: 15728224
Clinical Trial.